Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next ...

5 October 2026 · By · Wire by Fusion42

Published

5 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 5 October 2026 · Fusion42 review

HanchorBio has received FDA clearance for its IND application for HCB303, a next-generation trispecific immunotherapy targeting TIGIT ligands, PD-L1, and CD47, allowing initiation of a Phase 1 clinical trial in patients with advanced solid tumors.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now move to clinical trials with trispecific immunotherapy targeting a new TIGIT ligand strategy. Early trial data could open new pathways or reveal competitive edges in cancer immunotherapy development.

◆ Coverage

1 source · 5 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-clearancetrispecific-immunotherapyoncologyclinical-trialimmunotherapy